COVID-19 mRNA vaccines are not gene therapy. They do not alter your DNA, do not enter the cell nucleus under normal conditions, and are not classified as gene therapy by any major regulatory agency. The confusion is understandable, though, because mRNA vaccines and gene therapies both use genetic instructions to get cells to produce proteins. The similarity ends there.
What Gene Therapy Actually Does
Gene therapy modifies a person’s genes to treat or cure disease. The FDA defines it as a technique that can replace a faulty gene with a healthy copy, switch off a malfunctioning gene, or introduce an entirely new gene into the body. The key feature is that these changes happen at the DNA level, inside the cell nucleus, where your genetic code is stored. Because gene therapy edits or adds to that code, the changes are permanent. When a treated cell divides, its daughter cells inherit the modification.
Gene therapy products go through a specific regulatory pathway overseen by the FDA’s Center for Biologics Evaluation and Research, and they require a biologics license application for approval. They are used to treat genetic diseases like sickle cell disease or inherited blindness, conditions caused by a single broken gene that can be fixed or replaced.
How mRNA Vaccines Work Differently
An mRNA vaccine delivers a small piece of messenger RNA into your cells. This mRNA never needs to reach the nucleus. It works entirely in the cytoplasm, the fluid-filled space outside the nucleus where proteins are normally assembled. Once inside, the cell’s own machinery reads the mRNA and builds a harmless piece of the SARS-CoV-2 spike protein. Your immune system recognizes that protein as foreign and mounts a response, training itself to fight the real virus.
The mRNA itself has a very short half-life. Cells break it down quickly after it has been used, typically within hours to days. It does not persist, it does not replicate, and it is not passed to new cells when a cell divides. This is fundamentally different from gene therapy, where the goal is a lasting change to cellular DNA. The temporary nature of mRNA is actually the whole point: you need just enough spike protein to trigger an immune response, and then the instructions disappear.
Why the Two Get Confused
Both mRNA vaccines and some gene therapies deliver nucleic acids (genetic material) into cells. Both can use lipid nanoparticles, tiny fat-based bubbles, as a delivery vehicle. The COVID-19 vaccines from Pfizer and Moderna use lipid nanoparticles to protect the fragile mRNA and shuttle it into cells. A gene-silencing drug called Onpattro, which is a form of gene therapy, also uses lipid nanoparticles to deliver its payload to liver cells.
But the similarity in packaging does not make them the same product. The lipid nanoparticles used in vaccines are actually optimized differently than those used in gene therapies. Research has shown that formulations designed for gene-silencing payloads don’t work as well for mRNA delivery, and vice versa. Vaccine lipid nanoparticles appear to stimulate the immune system in ways that help the vaccine work, an effect that would actually be unwanted in a gene therapy context. The delivery system looks similar on the surface, but the engineering, the payload, and the biological goal are distinct.
Some of the confusion also stems from a broad academic definition. In drug delivery research, scientists sometimes use “gene therapy” as a catch-all term for any treatment that delivers nucleic acids to alter protein expression in cells. Under that expansive umbrella, mRNA vaccines would technically qualify. But this is a laboratory shorthand, not a regulatory or medical classification. In clinical and legal terms, vaccines and gene therapies occupy separate categories.
How Regulators Classify These Vaccines
The FDA reviewed and approved both Spikevax (Moderna) and Comirnaty (Pfizer-BioNTech) as vaccines for active immunization, not as gene therapy products. They were initially made available under emergency use authorization starting in December 2020, and both later received full approval through the standard biologics license application process. Moderna submitted its original application in September 2024, and the FDA review committee recommended approval. At no point in this process were the products evaluated or categorized as gene therapies.
The Reverse Transcription Question
One lab study published in 2022 did generate headlines by reporting that Pfizer’s mRNA vaccine could be reverse-transcribed into DNA inside a human liver cell line (Huh7 cells) within six hours of exposure. The researchers found that a genetic element naturally present in human cells, called LINE-1, became active after exposure to the vaccine mRNA and appeared to convert it into DNA fragments.
This finding is worth understanding in context. The experiment was conducted in a petri dish using a liver cancer cell line, not in living humans. Cancer cell lines behave very differently from normal human cells, and LINE-1 elements are known to be unusually active in cancer cells. The study authors themselves stated they did not know whether the DNA fragments actually integrated into the cell’s genome. No follow-up study in humans has demonstrated that vaccine mRNA integrates into human DNA. The normal biological barrier remains: mRNA works in the cytoplasm and is degraded before it would have a chance to interact with chromosomal DNA under typical cellular conditions.
What About Viral Vector Vaccines?
The Johnson & Johnson and AstraZeneca COVID vaccines used a different technology: adenovirus vectors. These are disabled viruses engineered to carry a DNA gene for the spike protein into your cells. Adenovirus vectors do enter the cell nucleus, which is where they differ from mRNA vaccines.
Adenoviruses have a long history in gene therapy research and are used in roughly 25% of all gene therapy clinical trials, primarily for cancer treatment. The same vector technology serves both purposes. However, adenovirus-based COVID vaccines were still regulated and classified as vaccines, not gene therapies, because their intent is immunization rather than permanent genetic modification. The adenovirus vectors used in these vaccines are replication-defective, meaning they cannot copy themselves, and the DNA they carry does not integrate into your chromosomes. It remains as a separate, temporary piece of DNA that the cell eventually discards.
The Core Distinction
The difference comes down to intent, mechanism, and duration. Gene therapy aims to make a lasting change to your genetic code to treat a disease caused by faulty genes. COVID vaccines aim to briefly instruct your cells to produce a viral protein so your immune system can learn to recognize it. Gene therapy alters DNA inside the nucleus permanently. mRNA vaccines deliver instructions to the cytoplasm that are destroyed within days. Gene therapy changes are inherited by daughter cells. Vaccine mRNA is not.
Calling mRNA vaccines “gene therapy” misrepresents what they do at every level: where they act in the cell, how long they last, what they change, and what they’re designed to accomplish. They share a common ancestor in that both technologies grew out of advances in nucleic acid research, but the products themselves are fundamentally different tools built for fundamentally different jobs.